Contact
Please use this form to send email to PR contact of this press release:
Kamada Submits Proposed Phase 3 Protocol to FDA for Inhaled Alpha-1 Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease
TO: